Abstract:In this study, the natural molecular history of matched primary and recurrent tumors of 19 patients with IDH‐mutant, 1p19q non‐codeleted astrocytomas without pressure of temozolomide or radiotherapy was studied. Samples were examined for DNA methylation profiling and copy number variations, gene mutations and ALT. Recurrences were characterized by new CNVs not present in the primary tumors. Few novel mutations were identified in recurrences. CDKN2A homozygous deletion, MYC or PDGFRA focal and non‐focal gain were found at recurrences. Our findings improve the understanding of the molecular life history of IDH‐mutant astrocytomas. Hypermutation and malignant transformation are potential complications arising from temozolomide treatment of IDH‐mutant gliomas. However, the natural history of IDH‐mutant low‐grade gliomas without temozolomide treatment is actually under‐studied. We retrieved retrospectively from our hospitals paired tumors from 19 patients with IDH‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas where no interim adjuvant treatment with either temozolomide or radiotherapy was given between primary resections and first recurrences. Tissues from multiple recurrences were available from two patients and radiotherapy but not temozolomide was given before the last specimens were resected. We studied the natural molecular history of these low‐grade IDH‐mutant astrocytomas without pressure of temozolomide with DNA methylation profiling and copy number variation (CNV) analyses, targeted DNA sequencing, TERTp sequencing, FISH for ALT and selected biomarkers. Recurrences were mostly higher grades (15/19 patients) and characterized by new CNVs not present in the primary tumors (17/19 cases). Few novel mutations were identified in recurrences. Tumors from 17/19 (89.5%) patients showed either CDKN2A homozygous deletion, MYC or PDGFRA focal and non‐focal gains at recurrences. There was no case of hypermutation. Phylogenetic trees constructed for tumors for the two patients with multiple recurrences suggested a lack of subclone development in their evolution when under no pressure from temozolomide. In summary, our studies demonstrated, in contrast to the phenomenon of temozolomide‐induced hypermutation, IDH‐mutant, 1p19q non‐codeleted Grade 2 astrocytomas which had not been treated by temozolomide, acquired new CNVs at tumor recurrences. These findings improve our understanding of the molecular life history of IDH‐mutant astrocytomas.

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma

Epco-26. Longitudinal Single-Cell Analyses Identify Drivers Of Genetic, Epigenomic, And Cellular Evolution In Idh-Mutant Glioma

Path-29. Longitudinal Epigenomic Evolution Of Idh-Wildtype Glioblastoma

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design

Epco-34. Deciphering The Longitudinal Trajectories Of Glioblastoma By Integrative Single-Cell Genomics

Epco-20. Mutant Idh Inhibitors Induce Lineage Differentiation In Idh-Mutant Oligodendroglioma

Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

Multi-scale signaling and tumor evolution in high-grade gliomas

Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis

Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping

Global DNA Methylation Profiling Reveals Chromosomal Instability in IDH-mutant Astrocytomas

The molecular history of IDH‐mutant astrocytomas without adjuvant treatment

Using AI-Based Evolutionary Algorithms to Elucidate Adult Brain Tumor (Glioma) Etiology Associated with IDH1 for Therapeutic Target Identification

TMOD-25. MODELING IDH1-MUTATED GLIOMAS: GENERATION, CHARACTERIZATION AND THERAPEUTIC SENSITIVITIES OF SEVEN PATIENT-DERIVED IDH1-MUTANT GLIOMA CELL LINES

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

Tmic-26. Immune Cell Dynamics Within Gliomas: The Influence Of Grade And Idh Status

IDH-mutant gliomas with additional class-defining molecular events